New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Ultragenyx Pharmaceutical Inc.
RARE
Shape
US Flag

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

5B

Biotechnology

Next Earning date - 07 Nov 2024

5B

Biotechnology

Next Earning date - 07 Nov 2024

53.82USD
Shape-1.00 ( -1.82%)
favorite-chart

Relative Strenght

15
favorite-chart

Volume Buzz

-40%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

11%

Quote Panel

Shape
Updated October 26, 2024
1W -1.18 % 1M -1.12 % 3M 18.97 % 1Y 64.04 %

Key Metrics

Shape
  • Market Cap

    4.96B


  • Shares Outstanding

    92.17M


  • Share in Float

    86.21M


  • Dividende

    0


  • Earning Date

    07 Nov 2024


  • Price Target

    53.82


  • Average Volume

    675632


  • Beta

    0.565


  • Range

    32.55-60.37


  • Industry

    Biotechnology


  • Website

    https://www.ultragenyx.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

10.31x

P/S Ratio

10.78x

P/B Ratio

2.1

Debt/Equity

-121.6%

Net Margin

$-7.2

EPS

How RARE compares to sector?

P/E Ratio

Relative Strength

Shape

RARE

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$627M

Shape326%

2025-Revenue

$5.31

Shape-249%

2025-EPS

$627M

Shape-483%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Evercore ISI

upgrade

Previous: Not converted

2023-06-06

Now: Outperform

Piper Sandler

downgrade

Previous: Overweight

2023-06-06

Now: Neutral

Morgan Stanley

downgrade

Previous: Overweight

2023-06-06

Now: Underweight

RBC Capital

upgrade

Previous: Sector Perform

2023-06-06

Now: Outperform

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-2.43
vs -1.08

Q4.22

arrow
arrow

N/A

-2.16
vs -1.79

Q1.23

arrow
arrow

N/A

-2.33
vs -2.19

Q2.23

arrow
arrow

N/A

-2.25
vs -2.26

Q3.23

arrow
arrow

N/A

-2.23
vs -2.43

Q4.23

arrow
arrow

N/A

-1.52
vs -2.16

Q1.24

arrow
arrow

N/A

-2.03
vs -2.33

Q2.24

arrow
arrow

N/A

-1.52
vs -2.25

Q3.24

arrow
arrow

N/A

-1.48
vs -2.23

Q4.24

arrow
arrow

N/A

-1.40
vs -1.52

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

+11%

90.7M  vs 81.6M

Q4.22

arrow
arrow

+24%

103.3M  vs 83.4M

Q1.23

arrow
arrow

+26%

100.5M  vs 79.9M

Q2.23

arrow
arrow

+21%

108.3M  vs 89.3M

Q3.23

arrow
arrow

+8%

98.1M  vs 90.7M

Q4.23

arrow
arrow

+23%

127.4M  vs 103.3M

Q1.24

arrow
arrow

+8%

108.8M  vs 100.5M

Q2.24

arrow
arrow

+36%

147M  vs 108.3M

Q3.24

arrow
arrow

+38%

135.3M  vs 98.1M

Q4.24

arrow
arrow

+15%

146.3M  vs 127.4M

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-52%

-0.52
vs -0.23

Q4.22

arrow
arrow

-43%

-0.43
vs -0.52

Q1.23

arrow
arrow

-74%

-0.74
vs -0.43

Q2.23

arrow
arrow

-124%

-1.24
vs -0.74

Q3.23

arrow
arrow

-503%

-5.03
vs -1.24

Q4.23

arrow
arrow

-45%

-0.45
vs -5.03

Q1.24

arrow
arrow

-122%

-1.22
vs -0.45

Q2.24

arrow
arrow

-30%

-0.30
vs -1.22

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

237

237
vs 224

6%

Q4.22

arrow
arrow

238

238
vs 237

0%

Q1.23

arrow
arrow

237

237
vs 238

0%

Q2.23

arrow
arrow

253

253
vs 237

7%

Q3.23

arrow
arrow

235

235
vs 253

-7%

Q4.23

arrow
arrow

251

251
vs 235

7%

Q1.24

arrow
arrow

279

279
vs 251

11%

Q2.24

arrow
arrow

277

277
vs 279

-1%

Earnings Growth

Latest News